

DRAGON PHARMACEUTICALS INC
Form 3
January 18, 2005

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
 Han Yanlin
 (Last) (First) (Middle)

2. Date of Event Requiring Statement
 (Month/Day/Year)
 01/12/2005

3. Issuer Name and Ticker or Trading Symbol
 DRAGON PHARMACEUTICALS INC [DRUG]

4. Relationship of Reporting Person(s) to Issuer
 (Check all applicable)

5. If Amendment, Date Original Filed(Month/Day/Year)

C/O DRAGON PHARMACEUTICAL INC., 1055 WEST HASTINGS, SUITE 1900
 (Street)

Director 10% Owner
 Officer Other
 (give title below) (specify below)
 Chief Executive Officer

VANCOUVER, BC V6E 2E9
 (City) (State) (Zip)

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	31,151,403 ⁽¹⁾	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security	4. Conversion or Exercise	5. Ownership Form of	6. Nature of Indirect Beneficial Ownership (Instr. 5)
--	--	--	---------------------------	----------------------	---

Edgar Filing: DRAGON PHARMACEUTICALS INC - Form 3

	Date Exercisable	Expiration Date	(Instr. 4)	Amount or Number of Shares	Price of Derivative Security	Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	
			Title				
Additional Dragon Closing Shares ⁽²⁾	Â ⁽²⁾	Â ⁽²⁾	Common Stock	2,997,682	\$ 0		D Â

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Han Yanlin C/O DRAGON PHARMACEUTICAL INC. 1055 WEST HASTINGS, SUITE 1900 VANCOUVER, Â A1 Â V6E 2E9	Â X	Â	Â Chief Executive Officer	Â

Signatures

Yanlin Han by Maggie Deng pursuant to a power of attorney 01/18/2005

⁽²⁾Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
18,573,384 shares are held in escrow to be released in two installments on the first and second anniversary dates from January 12, 2005,
- (1) provided there are no claims made by the Issuer against Reporting Person in connection with the Oriental Wave Share Purchase Agreement.
Under the terms of the June 11, 2004 Share Purchase Agreement, Mr. Han received Additional Closing Dragon Shares in order to maintain his pro rata interest in the Company in the event certain options and warrants outstanding as of the closing date are subsequently
- (2) exercised. The Additional Closing Dragon Shares may be issued or cancelled depending on whether or not such outstanding options or warrants are exercised or cancelled. Such Additional Closing Dragon Shares are held in escrow and are not assumed outstanding until released from escrow.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.